Skip to main content
NIH funding notice RFA-HD-22-019

User-Based Design to Aid in Contraceptive Development by Small Business (R43 Clinical Trial Not Allowed)

Closed on July 29, 2021.

Posted
March 29, 2021
Close date
July 29, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $508,835 in first-year total cost, median $254,418.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 EMNR-A (55)]2

Most frequent institutions

  1. DARE BIOSCIENCE, INC.1
  2. MUCOMMUNE, LLC1
Competing awards under RFA-HD-22-019 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring1R43HD108823-01KUSHIRO, KEIICHIROMUCOMMUNE, LLC, NC$259,499ZRG1
2022Defining end-user preferences among US women to optimize the design of a long-acting injectable hormonal contraceptive1R43HD108820-01FRIEND, DAVID RDARE BIOSCIENCE, INC., CA$249,336ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-HD-22-019: User-Based Design to Aid in Contraceptive Development by Small Business (R43 Clinical Trial Not Allowed) | ScienceDex | ConductScience